We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$216M 10.65%
17,556,586
+1,462,800
+9% +$13.6M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$166M 8.19%
11,012,561
-1,031,371
-9% -$13.6M
PBYI icon
3
Puma Biotechnology
PBYI
$468M
$109M 5.36%
906,642
+46,186
+5% +$4.3M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$100M 4.95%
1,843,733
+1,178,594
+177% +$60.3M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$82.1M 4.05%
996,610
+232,221
+30% +$18.4M
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$79.3M 3.91%
6,476,766
+4,252,955
+191% +$44.3M
AZN icon
7
AstraZeneca
AZN
$252B
$76.1M 3.75%
+1,123,150
New +$71M
INSM icon
8
Insmed
INSM
$25.9B
$62.2M 3.07%
1,991,646
+1,979,266
+15,988% +$37.7M
IMGN
9
DELISTED
Immunogen Inc
IMGN
$61.7M 3.04%
8,061,497
+2,848,761
+55% +$18.9M
RGNX icon
10
Regenxbio
RGNX
$638M
$55M 2.71%
1,667,672
-50,999
-3% -$1.15M
PEN icon
11
Penumbra
PEN
$12.7B
$51.1M 2.52%
565,511
-365,933
-39% -$31.5M
WVE icon
12
Wave Life Sciences
WVE
$993M
$49.3M 2.43%
2,267,707
+43,300
+2% +$870K
ATRA icon
13
Atara Biotherapeutics
ATRA
$92.3M
$47.8M 2.36%
115,588
+6,226
+6% +$2.35M
LIVN icon
14
LivaNova
LIVN
$4.43B
$44.3M 2.19%
632,488
+420,460
+198% +$26.6M
CNC icon
15
Centene
CNC
$32B
$39.2M 1.93%
809,200
+12,800
+2% +$551K
ICUI icon
16
ICU Medical
ICUI
$4.38B
$37.5M 1.85%
201,750
+69,245
+52% +$12.1M
AET
17
DELISTED
Aetna Inc
AET
$37.2M 1.83%
+233,837
New +$36.5M
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
$36.1M 1.78%
1,289,332
-170,284
-12% -$3.7M
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$34.5M 1.7%
2,051,487
-104,462
-5% -$1.7M
GWPH
20
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$34.4M 1.69%
338,536
-106,400
-24% -$11.4M
EHTH icon
21
eHealth
EHTH
$38.4M
$32M 1.58%
1,337,623
+114,289
+9% +$2.33M
MOH icon
22
Molina Healthcare
MOH
$10.4B
$31.7M 1.56%
461,074
-367,500
-44% -$23.9M
PRAH
23
DELISTED
PRA Health Sciences, Inc.
PRAH
$30.6M 1.51%
+402,014
New +$30.4M
ELGX
24
DELISTED
Endologix Inc
ELGX
$29.2M 1.44%
654,468
+17,638
+3% +$804K
NITE
25
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$28.8M 1.42%
+1,769,346
New +$38.2M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.